Global Weight Loss Drug Revolution Begins as Generic Ozempic Launches Outside US

Patent Expiry Triggers Mass Generic Launch

The diabetes and weight loss drug revolution has officially begun, but not where American patients might hope. Patent protections on semaglutide—sold as Ozempic for diabetes and Wegovy for weight loss—expire Saturday in several of the world's most populous countries, opening the door to generic versions in India almost immediately and in China, Canada, Brazil, Turkey, and South Africa in the months ahead. Together, those markets cover about 40% of humanity and hundreds of millions of people living with obesity or diabetes.

The first wave of generic versions of Novo Nordisk's GLP-1 weight-loss drugs launched in India over the weekend, with at least five domestic drugmakers undercutting the original price by up to 80%. Sun Pharmaceutical, one of the top generics manufacturers in the world, on Saturday launched a generic semaglutide for as low as 750 rupees ($8) for a weekly injection, or about 3,400 rupees per month. That compares with Novo's retail price of between 8,800 and 10,000 rupees in India, depending on the dosage.

Dozens of manufacturers have been racing to get their products approved. The aggressive competition has created what industry analysts describe as a chaotic marketplace, with "chaotic" next few weeks expected to be "overwhelming prescribers with aggressive marketing campaigns and varying device quality."

Americans Face Decade-Long Wait

While patients in major global markets gain access to affordable alternatives, Americans and most Europeans, however, face a long wait: patent-term extensions and other protections in those regions mean true generics for Ozempic and Wegovy likely won't arrive until the early 2030s, a delay critics say will cost patients and taxpayers tens of billions of dollars. The earliest possible US launch date for a generic semaglutide is around 2033, based on active patents protecting Ozempic and its pen injector design.

The list price for Ozempic® is about $998 per month. This stark contrast in pricing and availability creates what experts warn could become "a two-tier system whereby people who can't afford the more expensive drugs are only able to use drugs with less strong evidence of benefit." The situation is particularly frustrating given that semaglutide is the world's second-best selling prescription medicine, with combined sales of $26bn in 2024 and growing annually at a staggering 40%.

Global Impact Beyond Borders

The implications extend far beyond the countries where patents have expired. India supplies more than half of Africa's generic medicines, and cheaper semaglutide could become a lifeline for countries where obesity is rising rapidly but treatment remains unaffordable. Dr. Reddy's Laboratories has so far launched semaglutide for treating diabetes at around 4,200 rupees per month and plans to expand to Canada, Turkey and Brazil this year.

The transformation is already visible in clinical practice. More than 50 people walk into endocrinologist Nadeem Rais's office every week seeking weight-loss injections. "We have around 70 to 80 patients on active treatment right now," he told AFP. "When generics come out and prices drop, that could go up to 200 easily."

Market Disruption Accelerates

The shift is a blow to Novo Nordisk, already under pressure from Eli Lilly's rival drugs and from gray-market compounded versions in the US. Even as semaglutide remains protected from generic competition in the U.S. – its largest market by far– until 2032, patent expirations in India, Canada, Brazil, and China this year are likely to have a sizable impact on its revenue. In February, Novo warned that sales could decline by 5% to 13% in 2026.

The global pharmaceutical landscape is witnessing an unprecedented shift as access to life-changing medications becomes increasingly democratized in emerging markets while remaining prohibitively expensive in wealthy nations. This reversal of traditional pharmaceutical economics signals a new era where innovation and affordability may no longer be mutually exclusive, at least for those willing to look beyond their home markets for treatment options.